semaglutide for heart health Heart disease is the leading cause of death for people with diabetes, making cardiovascular protection a key factor
Quality sleep allows your body to process the medication effectively, improving appetite control and energy levels
Across the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Lillys investigational triple agonist delivered up to 22.6% mean weight loss at 80 weeks, alongside robust glycaemic improvement and broad cardiometabolic risk-factor reductions
Interestingly, the same team has found that mice deficient of the key enzyme involved in the IGN (i.e., glucose-6 phosphatase) exhibit increased basal sympathetic tone but also develop hypothalamic resistance to leptin, suggesting again a key link with the regulation of food intake and energy homeostasis
The SELECT trial showed it can reduce the risk by roughly 20%
For example, in one trial a high-dose (2.4 mg) semaglutide injection helped individuals lose about 15% of their body weight on average over ~16 months , whereas those on placebo lost only a few percent